BioModelsapplication/xmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL2109110003?filename=Rommelfanger2011%20Gompertz.xmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL2109110003?filename=Rommelfanger2011%20Gompertz.cpsprimaryOK200Emilia ChenNon-curatedordinary differential equation modelMelanomaL2V4https://www.ebi.ac.uk/biomodels/MODEL210911000321918546falseBioModelsSBMLModelsRommelfanger2011 Gompertz model of melanoma tumor therapy with vesicular stomatitis virus2012MODEL2109110003Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli DRommelfanger DM21918546,
Tumor selective, replication competent viruses are being tested for cancer gene therapy. This approach introduces a new therapeutic paradigm due to potential replication of the therapeutic agent and induction of a tumor-specific immune response. However, the experimental outcomes are quite variable, even when studies utilize highly inbred strains of mice and the same cell line and virus. Recognizing that virotherapy is an exercise in population dynamics, we utilize mathematical modeling to understand the variable outcomes observed when B16ova malignant melanoma tumors are treated with vesicular stomatitis virus in syngeneic, fully immunocompetent mice. We show how variability in the initial tumor size and the actual amount of virus delivered to the tumor have critical roles on the outcome of therapy. Virotherapy works best when tumors are small, and a robust innate immune response can lead to superior tumor control. Strategies that reduce tumor burden without suppressing the immune response and methods that maximize the amount of virus delivered to the tumor should optimize tumor control in this model system.. 5, 19.
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.emiliachen1@gmail.comUniversity of CambridgeTumor selective, replication competent viruses are being tested for cancer gene therapy. This approach introduces a new therapeutic paradigm due to potential replication of the therapeutic agent and induction of a tumor-specific immune response. However, the experimental outcomes are quite variable, even when studies utilize highly inbred strains of mice and the same cell line and virus. Recognizing that virotherapy is an exercise in population dynamics, we utilize mathematical modeling to understand the variable outcomes observed when B16ova malignant melanoma tumors are treated with vesicular stomatitis virus in syngeneic, fully immunocompetent mice. We show how variability in the initial tumor size and the actual amount of virus delivered to the tumor have critical roles on the outcome of therapy. Virotherapy works best when tumors are small, and a robust innate immune response can lead to superior tumor control. Strategies that reduce tumor burden without suppressing the immune response and methods that maximize the amount of virus delivered to the tumor should optimize tumor control in this model system.Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.Rommelfanger D M DM, Offord C P CP, Dev J J, Bajzer Z Z, Vile R G RG, Dingli D Dtreatment, Melanomas, Melanoma, vesicular stomatitis virus, Malignant Melanoma, Naevocarcinoma, disease management, malignant melanoma, vesicular stomatitis virus VSV, Malignant Melanomas, Tumor, Malignant, VSV.malignant Growth, Viridae, Residential, Transitions, dmBest1, Mobility, Activity, Laboratory, Burden, Stable Population, Tumor Weight, neoplasia, Mus domesticus, nonspecific immune response, Physical, CASP-14, Aging, sci, Tumor, House Mouse, DmelCG6264, Techniques, Decreases, Stationary, Population Pressures, melanoma, Physical Exercises, Method, Virus, Line, HOW, How, ARB, Population Replacement, Volume, Acute Exercises, l(3)j5D5, 24B, treatment, Aerobic Exercises, Theory, Immune Responses, vesicular stomatitis virus, reference sample, Somatic Genetic Therapies, Natural, cell process disease, tumor disease, Physical Activity, neoplasm (disease), Loads, stru, hypoplasia, Weights, Swiss Mice, l(3)S053606, procedures, Innate Immune Responses, CG10293, CA, Non-Specific Immunity, l(3)j5B5, Population Theory, Methodological Studies, Vira, malignant neoplasm, disease management, Therapies, variability of a physical quality, Strains, size of tumor, Tumor Volume, Theories, tumor, Tumor Loads, Exercises, Therapy, Genetic Therapy, malignancy, 0904/17, CG6264, Immunity, Stationary Populations, Native, mouse, Aerobic, neoplastic disease, Malignant Melanomas, Procedure, Somatic Genetic Therapy, Somatic Genetic, Genetic Therapies, Melanoma, SZ1, Gametic, Mini-ICE, Weight, organ system cancer, Population Decrease, Decrease, Physical Exercise, TU15B, Population Replacements, Lines, dBest1, Aerobic Exercise, Mus musculus, Populations, Replacements, Native Immunity, Gametic Genetic, Caspase-14 subunit p10, Somatic Gene Therapy, mice, dbest1, Swiss Mouse, Caspase-14 subunit p19, Somatic Gene, Rural-Urban Migration, Methodological, MICE, Natural Resistance, Methodological Study, experimental procedures, domesticus, Activities, organ system, Migrations, Replacement, Animal Viruses, anon-EST:Liang-2.39, Mouse, DNA, other neoplasm, cancer, Strains and Sprains, Innate, 3.4.22.-, Rural-Urban Migrations, Mobilities, Stable Populations, Migration, Demographic Transitions, Innate Immunity, Procedures, experimental, P62, cell type cancer, Training, Isometric, Gene, Rural-Urban, mini-ICE, Exercise Training, Population Theories, anon-WO0118547.380, Malignant, Population Decreases, Tumor Weights, Load, melanoma (disease), reduced, House, Studies, Mus musculus domesticus, system, Tumor Load, Animal, tiny, VSV, neoplasm, Sprains, Mice, Technique, malignant tumour, Neomalthusianism, Gametic Genetic Therapy, Somatic, Animal Virus, methods, anatomical systems, Genetic, l(3)s2612, Viruses, Swiss, Gametic Genetic Therapies, DNA Therapy, experimental section, VMD2, Naevocarcinoma, BMD, Population, Study, Malthusianism, Immune Response, Stable, DmelCG10293, Optimum, Optimum Population, Transition, Non Specific, Controlled, RP50, small, Controlling, Natural Immunity, clone 2.39, malignant, Sprain, Cell Lines, Exercise, vesicular stomatitis virus VSV, innate immunity, qkr, l(3)S090417, Cell, Demographic Transition, viruses, Melanomas, Gene Therapy, neoplastic growth, MT, Mus, body system., malignant neoplasm (disease), Pressure, Malignant Melanoma, KH93F, Strain, Resistance, Demographic, Acute Exercise, Optimum Populations, techniques, Isometric Exercises, connected anatomical system, Zoophaginae, who, Dbest, primary cancer, Rural Urban Migration, best, underdeveloped, Residential Mobility, Residential Mobilities, Stationary Population, House Mice, Dynamics, Who/How, Trainings, disease of cellular proliferation, malignant tumor, Exercise Trainings, Laboratory Mice, Isometric Exercise, Innate Immune Response, Acute, Physical Activities, Population Pressure, Pressures, malignant neoplastic disease, Non-Specific, Demographic Aging, qkr[93F], malignant melanoma, variable, Laboratory Mouse, BEST, methodologyFgf-r, treatment, 0844/01, vesicular stomatitis virus, PLATEST, lambdatop, DmelCG32134, Naevocarcinoma, D-FGFR, dFGFR, dev, vesicular stomatitis virus VSV, INSDC_feature:gene, Malignant Melanomas, dtk2, Tumor, Estimated, Dfr-2, Malignant, CG6714, DOI, BTL/FGFR2, CG32134, Commentary, CT20816, Melanomas, fgf-r, Melanoma, Publication, DmHD-311, FGFR, Malignant Melanoma, DFGF-R1, disease management, HD-311, Platelets., malignant melanoma, variability of a physical quality, l(3)00208, Viewpoint, Dtk2, Editorial Comment, VSV, Tk2, Btl, DFR2, FGFR1, doitreatment, Melanomas, Melanoma, vesicular stomatitis virus, Malignant Melanoma, Naevocarcinoma, disease management, variability of a physical quality., malignant melanoma, vesicular stomatitis virus VSV, Malignant Melanomas, VSV, Tumor, MalignantfalseRommelfanger2011 - Gompertz model of melanoma tumor therapy with vesicular stomatitis virus
This mathematical model is described by the publication:
Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. "Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling". Gene Ther. 2012 May;19(5):543-9.
doi: 10.1038/gt.2011.132.
Curation Comment:
Plots could not be reproduced as initial conditions for the simulations could not be found in the publication, nor estimated.
2021-09-112021-09-112021-09-11MODEL210911000321918546C15438C62713C94604960611276